CSL Limited will use Selexis Technologies for Development of Therapeutic Antibody
GENEVA, July 26, 2011 /PRNewswire via COMTEX/ -- Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited (asx:CSL Australia) has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012. This commercial license agreement provides CSL with the rights to use a cell line, generated using the Selexis SUREtechnology Platform, for the cGMP production of an undisclosed antibody.
"We are pleased CSL is moving forward with a production cell line generated using the SUREtechnology Platform," said Dr. Igor Fisch, CEO, Selexis SA. "This agreement represents Selexis' commitment to helping our clients bring biologic therapeutic drugs into the clinic. We look forward to continuing to work with CSL."
Terms of the agreement were not disclosed.
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development(TM) Technology Platform is based on Selexis Genetic Elements(TM) -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors(TM), Selexis SUREfection(TM) Transfection Methods, Selexis SUREvariant Screening(TM) and the proprietary Selexis SURE CHO-M Cell Line(TM).
For more information visit www.selexis.com
About CSL Limited
Headquartered in Melbourne, Australia, with major facilities in Germany, Switzerland and the U.S., CSL has more than 10,000 employees working in 27 countries. The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years of experience in the development and manufacture of vaccines and plasma protein biotherapies. In fiscal 2010, the company produced revenues of approximately A$4.5 billion.
For more information visit http://www.csl.com.au